TCM
SUPN icon

Tamarack Capital Management’s Supernus Pharmaceuticals SUPN Stock Holding History

Tamarack Capital Management’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-150,000
Closed -$2.55M – 38
2015
Q2 		$2.55M Buy
+150,000
New +$2.13M 0.29% 34

Other funds holding SUPN

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
RIM
Ranger Investment Management Dallas, Texas $1.38B AUM 24.55% 1-Year Est. Return
ACM
Apex Capital Management Dayton, Ohio $4.54B AUM 1.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM
MRM
Michael R. Murphy $255M AUM 0.87% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Tamarack Capital Management's SUPN Position: Q3 2015 in Review

Tamarack Capital Management sold out of Supernus Pharmaceuticals (SUPN) in Q3 2015, closing a stake of 150,000 shares — an estimated $2.55M sold.

Tamarack Capital Management first reported a position in SUPN in Q2 2015 and held it in 1 quarter. The position peaked at $2.55M in Q2 2015. 186 funds tracked by Wall St. Rank hold SUPN as of Q3 2015.

  • Tamarack Capital Management reported no remaining Supernus Pharmaceuticals position as of Q3 2015 after selling out during the quarter.
  • Tamarack Capital Management sold 150,000 Supernus Pharmaceuticals shares in Q3 2015, an estimated $2.55M.
  • Tamarack Capital Management first reported a position in Supernus Pharmaceuticals in Q2 2015 and held it in 1 quarter.
  • Tamarack Capital Management's Supernus Pharmaceuticals position peaked at $2.55M in Q2 2015.
  • 186 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q3 2015.

Based on Tamarack Capital Management's 13F filing for Q3 2015, filed 10 Nov 2015.